Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allegra Dry Syrup in Pediatric Atopic Dermatitis
NCT01244230Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fexofenadine in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Number of patients with adverse events at 4 weeks and Number of clinically significant abnormalities for laboratory findings at 4 weeks. Started Nov 2010; status: completed.
02
Drugs
fexofenadine
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01244230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244230.